Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2010

Open Access 01-12-2010 | Research

Heterologous SH3-p85β inhibits influenza A virus replication

Authors: Dan-gui Zhang, Wei-zhong Li, Ge-fei Wang, Yun Su, Jun Zeng, Chi Zhang, Xiang-xing Zeng, Xiao-xuan Chen, Yan-xuan Xu, Kang-sheng Li

Published in: Virology Journal | Issue 1/2010

Login to get access

Abstract

Phosphatidylinositol 3-kinase (PI3K)/Akt signalling pathway can support the replication of influenza A virus through binding of viral NS1 protein to the Src homology 3 (SH3) domain of p85β regulatory subunit of PI3K. Here we investigated the effect of heterologously overexpressed SH3 on the replication of different influenza A virus subtypes/strains, and on the phosphorylation of Akt in the virus-infected cells. We found that heterologous SH3 reduced replication of influenza A viruses at varying degrees in a subtype/strain-dependent manner and SH3 overexpression reduced the induction of the phosphorylation of Akt in the cells infected with PR8(H1N1) and ST364(H3N2), but not with ST1233(H1N1), Ph2246(H9N2), and Qa199(H9N2). Our results suggest that interference with the NS1-p85β interaction by heterologous SH3 can be served as a useful antiviral strategy against influenza A virus infection.
Appendix
Available only for authorised users
Literature
1.
Nelson MI, Viboud C, Simonsen L, Bennett RT, Griesemer SB, St George K, Taylor J, Spiro DJ, Sengamalay NA, Ghedin E, Taubenberger JK, Holmes EC: Multiple reassortment events in the evolutionary history of H1N1 influenza A virus since 1918. PLoS Pathog 2008, 4: e1000012. 10.1371/journal.ppat.1000012PubMedPubMedCentralCrossRef
2.
Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK, Shortridge KF: Human infection with influenza H9N2. Lancet 1999, 354: 916-917. 10.1016/S0140-6736(99)03311-5PubMedCrossRef
3.
Garcia-Sastre A: Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. Virology 2001, 279: 375-384. 10.1006/viro.2000.0756PubMedCrossRef
4.
Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P, Muster T: Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998, 252: 324-330. 10.1006/viro.1998.9508PubMedCrossRef
5.
Krug RM, Yuan W, Noah DL, Latham AG: Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology 2003, 309: 181-189. 10.1016/S0042-6822(03)00119-3PubMedCrossRef
6.
Hayman A, Comely S, Lackenby A, Murphy S, McCauley J, Goodbourn S, Barclay W: Variation in the ability of human influenza A viruses to induce and inhibit the IFN-beta pathway. Virology 2006, 347: 52-64. 10.1016/j.virol.2005.11.024PubMedCrossRef
7.
Hale BG, Jackson D, Chen YH, Lamb RA, Randall RE: Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling. Proc Natl Acad Sci USA 2006, 103: 14194-14199. 10.1073/pnas.0606109103PubMedPubMedCentralCrossRef
8.
Brazil DP, Yang ZZ, Hemmings BA: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004, 29: 233-242. 10.1016/j.tibs.2004.03.006PubMedCrossRef
9.
Cantley LC: The phosphoinositide 3-kinase pathway. Science 2002, 296: 1655-1657. 10.1126/science.296.5573.1655PubMedCrossRef
10.
Cooray S: The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. J Gen Virol 2004, 85: 1065-1076. 10.1099/vir.0.19771-0PubMedCrossRef
11.
J Yu, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM: Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 1998, 18: 1379-1387.CrossRef
12.
Cantrell DA: Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001, 114: 1439-1445.PubMed
13.
Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC: Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 2005, 30: 194-204. 10.1016/j.tibs.2005.02.008PubMedCrossRef
14.
Shin YK, Liu Q, Tikoo SK, Babiuk LA, Zhou Y: Influenza A virus NS1 protein activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by direct interaction with the p85 subunit of PI3K. J Gen Virol 2007, 88: 13-18. 10.1099/vir.0.82419-0PubMedCrossRef
15.
Shin YK, Li Y, Liu Q, Anderson DH, Babiuk LA, Zhou Y: SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K/Akt signaling pathway activation. J Virol 2007, 81: 12730-12739. 10.1128/JVI.01427-07PubMedPubMedCentralCrossRef
16.
Y Li, Anderson DH, Liu Q, Zhou Y: Mechanism of influenza A virus NS1 protein interaction with the p85beta, but not the p85alpha, subunit of phosphatidylinositol 3-kinase (PI3K) and up-regulation of PI3K activity. J Biol Chem 2008, 283: 23397-23409. 10.1074/jbc.M802737200CrossRef
17.
Hale BG, Kerry PS, Jackson D, Precious BL, Gray A, Killip MJ, Randall RE, Russell RJ: Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein. PNAS 2010, 107: 1954-1959. 10.1073/pnas.0910715107PubMedPubMedCentralCrossRef
18.
Ehrhardt C, Marjuki H, Wolff T, Nurnberg B, Planz O, Pleschka S, Ludwig S: Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence. Cell Microbiol 2006, 8: 1336-1348. 10.1111/j.1462-5822.2006.00713.xPubMedCrossRef
19.
Shin YK, Liu Q, Tikoo SK, Babiuk LA, Zhou Y: Effect of the phosphatidylinositol 3-kinase/Akt pathway on influenza A virus propagation. J Gen Virol 2007, 88: 942-950. 10.1099/vir.0.82483-0PubMedCrossRef
20.
Ehrhardt C, Wolff T, Pleschka S, Planz O, Beermann W, Bode JG, Schmolke M, Ludwig S: Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J Virol 2007, 81: 3058-3067. 10.1128/JVI.02082-06PubMedPubMedCentralCrossRef
21.
Zhirnov OP, Klenk HD: Control of apoptosis in influenza virus-infected cells by up-regulation of Akt and p53 signaling. Apoptosis 2007, 12: 1419-1432. 10.1007/s10495-007-0071-yPubMedCrossRef
22.
Ehrhardt C, Ludwig S: A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell Microbiol 2009, 11: 863-871. 10.1111/j.1462-5822.2009.01309.xPubMedCrossRef
23.
Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22: 8983-8998. 10.1038/sj.onc.1207115PubMedCrossRef
24.
Hale BG, Randall RE, Ortin J, Jackson D: The multifunctional NS1 protein of influenza A viruses. J Gen Virol 2008, 89: 2359-2376. 10.1099/vir.0.2008/004606-0PubMedCrossRef
25.
Twu KY, Noah DL, Rao P, Kuo RL, Krug RM: The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target. J Virol 2006, 80: 3957-3965. 10.1128/JVI.80.8.3957-3965.2006PubMedPubMedCentralCrossRef
26.
Li W, Wang G, Zhang H, Zhang D, Zeng J, Chen X, Xu Y, Li K: Differential suppressive effect of promyelocytic leukemia protein on the replication of different subtypes/strains of influenza A virus. Biochem Biophys Res Commun 2009, 389: 84-89. 10.1016/j.bbrc.2009.08.091PubMedCrossRef
Metadata
Title
Heterologous SH3-p85β inhibits influenza A virus replication
Authors
Dan-gui Zhang
Wei-zhong Li
Ge-fei Wang
Yun Su
Jun Zeng
Chi Zhang
Xiang-xing Zeng
Xiao-xuan Chen
Yan-xuan Xu
Kang-sheng Li
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2010
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-7-170

Other articles of this Issue 1/2010

Virology Journal 1/2010 Go to the issue

Research

Incidence of multiple Herpesvirus infection in HIV seropositive patients, a big concern for Eastern Indian scenario

Research

Co-receptor usage and prediction of v3 genotyping algorithms in hiv-1 subtype b' from paid blood donors experienced anti-retroviral therapy in chinese central province

Case Report

Current antibody-based immunoassay algorithm failed to confirm three late-stage AIDS cases in China: case report

Short report

Bovine herpesvirus 4 based vector as a potential oncolytic-virus for treatment of glioma

Study protocol

Molecular characterization of porcine circovirus 2 isolated from diseased pigs co-infected with porcine reproductive and respiratory syndrome virus

Research

Characterization of human adenovirus 35 and derivation of complex vectors
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits